When do we hear about Pelage February 2025 study results? 2/4/2025
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
community Pelage PP405: New Hair Growth from Inactive Follicular Units - Phase 2a results at AAD 2026
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
community Pelage Announces Positive Results of Phase 2a Trials for PP405
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
community Update July 2025] Most Promising Hair Loss Treatments in Clinical Trials
Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
Related Research
6 / 6 results
research PP405 in Alopecia: An Emerging Molecule worth Investigating
In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
research Recent Advances in Drug Development for Hair Loss
This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Regenerative Medicine Approaches for Engineering a Human Hair Follicle
This review discusses advancements in regenerative medicine for hair loss treatments, highlighting stem cell techniques for rejuvenating or creating hair follicles, but provides no new clinical results.
research Minoxidil: mechanisms of action on hair growth
This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
research Management of primary cicatricial alopecias: options for treatment
This review discusses evidence-based guidance for managing primary cicatricial alopecias but reports no new clinical results, highlighting significant gaps in knowledge and the need for more quality trials.